期刊文献+

马来酸曲美布汀联合双歧杆菌治疗功能性肠胀气疗效观察 被引量:3

Efficacy of trimebutine maleate combined with bifidobacterium in treatment of patients with overful gas in intestinal tract
下载PDF
导出
摘要 目的观察马来酸曲美布汀联合双歧杆菌对功能性肠胀气的疗效。方法将功能性肠胀气患者随机分为A、B两组,每组30例。A组服用马来酸曲美布汀联合双歧杆菌,B组仅服用双歧杆菌,疗程2周。结果治疗1周,A组症状积分明显下降(P<0.01),B组无明显变化(P>0.05)。治疗2周,A组症状积分下降更为明显(P<0.01),B组较治疗前明显下降(P<0.05),但高于A组(P<0.05)。A组总有效率明显高于B组(1周有效率:腹胀:53.3%VS 17.9%,伴随症状:58.3%VS 28.6%;2周有效率:腹胀:76.7%VS 42.9%,伴随症状:79.2%VS 45.5%)。结论马来酸曲美布汀联合双歧杆菌对功能性肠胀气有较好疗效。 Objecctive To evaluate the efficacy of trimebufine mateate combined with bifidobactefittm in treatment of ovefful gas in intestinal tract of patients with alimentray dyskinesia.Methods By using a randomized and controlled clinical trial,the patients were divided into trimebutine maleate combined with bifidobacterium group(A group, n = 30)and bifidobacterium group(B group, n = 30) . The treaanent duration was 2 weeks.Results The symptom scores in A group decreased significanfly( P 〈 0.01 )after 1 week treatment and more remarkably( P 〈 0.01)after 2 weeks treatment. In B group, tire symptom scores decreased significantly( P 〈 0.05)only after 2 weeks treatment, and higher than A group( P 〈 0.05). Total efficacy rate of A group were higher than B group( 1^st week efficacy rate: abdominal distension: 53.3% VS 17.9% .other symptoms: 58.3% VS 28.6% .2^nd week efficacy rate: abdomihal distension: 76.7% VS 42.9 %, other symptoms: 79.2 % VS 45.5 % ). Conclusion Trimebutine maleate combined with bifidobactefium is effective in treatment of patients with overful gas in intestinal tract.
作者 斯锞 廖文
出处 《四川医学》 CAS 2009年第1期19-21,共3页 Sichuan Medical Journal
关键词 马来酸曲美布汀 双歧杆菌 功能性肠胀气 trimebutine maleate bifidobactefium overful gas
  • 相关文献

参考文献5

  • 1罗金燕.功能性肠病与罗马Ⅲ[J].胃肠病学,2006,11(12):739-740. 被引量:23
  • 2Serra-Pueyo J.Intestinal gas and functional disorders of the gastrointestinal tract[ J]. Gastroenterol Hepatol, 2003,26(4 ) : 263 - 269
  • 3Laugel C, Rafidison P, Potard G, et al. Modulated release of triterpenic compounds from a O/W/O multiple emulsion formulated with dimethicones: infrared spectrophotometric and differential calorimetric approaches[J]. J Control Release,2000,63(1):717
  • 4周连鸿.肠道微生态系统[J].胃肠病学,2003,8(1):35-37. 被引量:44
  • 5Thompson WG,Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain [ J]. Gut, 1999,45 (Suppl2) : 43 -47

二级参考文献22

  • 1[2]Collins MD, Gibson GR. Probiotics, prebiotics,and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr, 1999,69: 1052S~1057S.
  • 2[6]Lievin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser JR, Servin AL. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut, 2000,47: 646~652.
  • 3[8]Shida K, Makino K, Morishita A, Takamizawa K,Hachimura S, Ametani A, Sato T, Kumagai Y,Habu S, Kaminogawa S. Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. Int Arch Allergy Immunol, 1998,115: 278~287.
  • 4[9]Coconnier MH, Lievin V, Bernet-Camard MF, Hudault S, Servin AL. Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Antimicrob Agents Chemother, 1997, 41:1046 ~ 1052.
  • 5[10]Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol, 1995, 79: 475~479.
  • 6Wald A,Hinds JP,Caruana BJ.Psychological and physiological characteristics of patients with severe idiopathic constipation.Gastroenterology,1989,97:932~937.
  • 7Jones MP,Talley NJ,Nuyts G,Dubois D.Lack of objective evidence of efficacy of laxatives in chronic constipation.Dig Dis Sci,2002,47:2222~2230.
  • 8Lederle FA,Busch DL,Mattox KM,West MJ,Aske DM.Cost-effective treatment of constipation in the elderly:a randomized double-blind comparison of sorbitol and lactulose.Am J Med,1990,89:597~601.
  • 9Johanson JF,Wald A,Tougas G,Chey WD,Novick JS,Lembo AJ,Fordham F,Guella M,Nault B.Effect of tegaserod in chronic constipation:a randomized,doubleblind,controlled trial.Clin Gastroenterol Hepatol,2004,2:796~805.
  • 10Kamm MA,Muller-Lissner S,Talley NJ,Tack J,Boeckxstaens G,Minushkin ON,Kalinin A,Dzieniszewski J,Haeck P,Fordham F,Hugot-Cournez S,Nault B.Tegaserod for the treatment of chronic constipation:a randomized,double-blind,placebo-controlled multinational study.Am J Gastroenterol,2005,100:362~372.

共引文献65

同被引文献19

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部